Evidence map›Paper›PMID 25853696›Full record

ArticleAmerican journal of respiratory and critical care medicine2015

Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.

Nils P Nickel, Edda Spiekerkoetter, Mingxia Gu, Caiyun G Li, Hai Li, Mark Kaschwich, Isabel Diebold, Jan K Hennigs, Ki-Yoon Kim, Kazuya Miyagawa and 9 more

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 159 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Signaling pathways and targeted therapy for pulmonary hypertension.Signal transduction and targeted therapy · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. New Drugs and Therapies in Pulmonary Arterial Hypertension.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Article
  17. Endogenous Retroviral Elements Generate Pathologic Neutrophils in Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2022
    Article
  18. Nets, pulmonary arterial hypertension, and thrombo-inflammation.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
  19. Review
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Nils P Nickel1 Department of Pediatrics and.
Edda Spiekerkoetter
Mingxia Gu
Caiyun G Li
Hai Li
Mark Kaschwich
Isabel Diebold
Jan K Hennigs
Ki-Yoon Kim
Kazuya Miyagawa
Lingli Wang
Aiqin Cao
Silin Sa
Xinguo Jiang
Raymond W Stockstill
Mark R Nicolls
Roham T Zamanian
Richard D Bland
Marlene Rabinovitch
Cardiovascular Institute of the South · USPediatrics and Genetics · USStanford Medicine · US

Funding

VRAC and Rho in pulmonary EC proliferationP01HL014985 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI STENMARK, KURT R. · 1985 to 2019
$35.1M
The Cellular Response to Elafin in PAHP01HL108797 · NHLBI · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2011 to 2021
$19.7M
Pulmonary Hypertension in Genetically Modified MiceR01HL074186 · NHLBI · STANFORD UNIVERSITY · PI RABINOVITCH, MARLENE · 2004 to 2022
$10.4M
Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
Critical Role for Microvasculature in Airway TransplantationR01HL095686 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI NICOLLS, MARK ROBERT · 2010 to 2022
$4.7M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed DrugsR01HL128734 · NHLBI · STANFORD UNIVERSITY · PI SPIEKERKOETTER, EDDA FRAUKE · 2016 to 2020
$2.1M
Modulating BMPRII Signaling in Pulmonary Arterial HypertensionK08HL107450 · NHLBI · STANFORD UNIVERSITY · PI SPIEKERKOETTER, EDDA FRAUKE · 2011 to 2015
$606k
An Autoimmune Basis for Pulmonary HypertensionR56HL082662 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI NICOLLS, MARK ROBERT · 2014 to 2014
$387k
NHLBI NIH HHS 1K08HL107450-01NHLBI NIH HHS 5P01HL108797NHLBI NIH HHS K08 HL107450NHLBI NIH HHS P01 HL014985NHLBI NIH HHS P01 HL108797NHLBI NIH HHS R01 HL074186NHLBI NIH HHS R01 HL095686NHLBI NIH HHS R01 HL128734NHLBI NIH HHS R24 HL123767NHLBI NIH HHS R56 HL082662NHLBI NIH HHS U10 HL109250
6 · The paper itself

Abstract

rationalePulmonary arterial hypertension is characterized by endothelial dysfunction, impaired bone morphogenetic protein receptor 2 (BMPR2) signaling, and increased elastase activity. Synthetic elastase inhibitors reverse experimental pulmonary hypertension but cause hepatotoxicity in clinical studies. The endogenous elastase inhibitor elafin attenuates hypoxic pulmonary hypertension in mice, but its potential to improve endothelial function and BMPR2 signaling, and to reverse severe experimental pulmonary hypertension or vascular pathology in the human disease was unknown.

objectivesTo assess elafin-mediated regression of pulmonary vascular pathology in rats and in lung explants from patients with pulmonary hypertension. To determine if elafin amplifies BMPR2 signaling in pulmonary artery endothelial cells and to elucidate the underlying mechanism.

methodsRats with pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and hypoxia (Sugen/hypoxia) as well as lung organ cultures from patients with pulmonary hypertension were used to assess elafin-mediated reversibility of pulmonary vascular disease. Pulmonary arterial endothelial cells from patients and control subjects were used to determine the efficacy and mechanism of elafin-mediated BMPR2 signaling. MEASUREMENTS AND MAIN

resultsIn Sugen/hypoxia rats, elafin reduced elastase activity and reversed pulmonary hypertension, judged by regression of right ventricular systolic pressure and hypertrophy and pulmonary artery occlusive changes. Elafin improved endothelial function by increasing apelin, a BMPR2 target. Elafin induced apoptosis in human pulmonary arterial smooth muscle cells and decreased neointimal lesions in lung organ culture. In normal and patient pulmonary artery endothelial cells, elafin promoted angiogenesis by increasing pSMAD-dependent and -independent BMPR2 signaling. This was linked mechanistically to augmented interaction of BMPR2 with caveolin-1 via elafin-mediated stabilization of endothelial surface caveolin-1.

conclusionsElafin reverses obliterative changes in pulmonary arteries via elastase inhibition and caveolin-1-dependent amplification of BMPR2 signaling.

Indexed as

AnimalsApoptosisBone Morphogenetic Protein Receptors, Type IICaveolin 1Cells, CulturedElafinEndothelial CellsHumansHypertension, PulmonaryMyocytes, Smooth MusclePancreatic ElastaseProtease InhibitorsRatsSignal TransductionBone Morphogenetic Protein Receptors, Type IICaveolin 1ElafinPancreatic ElastaseProtease Inhibitorsapelinarterial smooth muscle cellsendothelial cell apoptosisneutrophil elastase inhibitionpulmonary vascular regeneration and angiogenesis

Identifiers

PMID25853696
PMCPMC4476518
OpenAlexW2117357690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.